Intrafusin (Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine)

The blend supplies a spectrum of essential and conditionally essential amino acids that replenish intracellular pools, stimulate protein synthesis pathways such as mTOR, and serve as precursors for neurotransmitters and antioxidants. This supports tissue repair, immune function, and metabolic stability during catabolic stress.

Dosing of Intrafusin is individualized. The prescribing clinician determines the amount, infusion rate, and duration based on the patient’s weight, clinical condition, and overall nutritional plan. No fixed regimen is provided in public literature.

Safety data for Intrafusin in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To request Intrafusin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Intrafusin offers a comprehensive amino acid profile in a single intravenous bag, whereas some alternatives provide separate amino acid and dextrose solutions. This can simplify compounding and reduce preparation time, but clinicians must still tailor the overall nutrient composition to each patient’s metabolic needs.

Intrafusin must be stored refrigerated between 2 °C and 8 °C. Keep the container in its original packaging, protect it from light, and avoid freezing or vigorous shaking. Once removed from refrigeration, use the product within the time frame specified by the manufacturer.

Intrafusin is administered intravenously, typically via a controlled infusion pump. The infusion rate is set according to the prescribed dose and patient tolerance, and the solution is delivered through a sterile catheter or central line under aseptic conditions.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, hyperammonemia, metabolic acidosis, acute renal dysfunction, and significant electrolyte disturbances. Prompt recognition and discontinuation of the infusion are essential if any of these events occur.

Intrafusin should be avoided in patients with known hypersensitivity to any of its amino acid components, in those with uncontrolled severe hepatic failure, and in individuals where the risk of hyperammonemia outweighs potential benefit. Clinical judgment is required for all contraindications.